Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192550 · ClinicalTrials.gov registry record · NA
Functional Usability and Feasibility Testing of the Profound Matrix™ System
A NA study of Wrinkle and Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Candela Corporation.
- Completed
- Registry status
- NA
- Development phase
- 193
- Enrollment target
- 5
- Study locations
NCT06192550: Completed NA study of Wrinkle and Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Candela Corporation.
NCT06192550 is a NA study of Wrinkle and Acne Scars - Mixed Atrophic and Hypertrophic that has completed, run by Candela Corporation. The registered enrollment target is 193 participants, above the 112-participant average among 25 other Wrinkle trials with a reported enrollment target (72% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06192550, a NA study of Wrinkle and Acne Scars - Mixed Atrophic and Hypertrophic, has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 193 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up to five (5) treatments with the Sublime and/or Sublative Radiofrequency (RF) applicators.
Primary Outcome
Perceived improvement in overall appearance according to the 5-point Global Aesthetic Improvement Scale from -1= Worse to 3= Very Much Improved as assessed by investigator at study endpoint
Conditions Studied
Interventions
- DEVICE Profound Matrix™ System
Study Locations (5)
New York
- NY Derm - New York
- OptiSkin - New York
Massachusetts
- Candela Institue for Excellence - Marlborough
North Carolina
- Laser & Vein Specialists of the Carolinas - Charlotte
Other
- Syneron Medical - Yokneam Illit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2023-12-29 |
| Phase | NA |
What the finished NCT06192550 record still lists
NCT06192550 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 25 other Wrinkle trials with a reported enrollment target (72% higher).
The record links to 2 conditions, with Wrinkle appearing as the primary indexed condition, and to 1 intervention - of which Profound Matrix™ System is the first listed.
NCT06192550 lists 5 locations in 4 states (New York, Massachusetts, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06192550 about?
NCT06192550 is a clinical study titled "Functional Usability and Feasibility Testing of the Profound Matrix™ System". This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up ...
What is the current status of trial NCT06192550?
This trial is currently completed. It is a NA study. The enrollment target is 193 participants. The study started on 2020-10-28. Estimated completion is 2023-12-29.
What conditions does trial NCT06192550 study?
This clinical trial studies the following conditions: Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic.
What interventions are being tested in trial NCT06192550?
The interventions under investigation include: Profound Matrix™ System (DEVICE).
Who is sponsoring clinical trial NCT06192550?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06192550 being conducted?
This trial has 5 study locations across Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wrinkle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06192550's enrollment target sits among peer trials
193 6th of 25 higher than 20 of 25 other Wrinkle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles
RECRUITING · NA
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
RECRUITING · NA
-
The Effects of Almond on Facial Skin Collagen and Wrinkles
RECRUITING · NA
-
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
RECRUITING · NA
-
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI